These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39108764)

  • 1. Combination Therapy of Lenvatinib and Hepatic Arterial Infusion Chemotherapy Using Cisplatin With Lipiodol and 5-Fluorouracil: A Potential Breakthrough Therapy for Unresectable Advanced Hepatocellular Carcinoma.
    Maruta S; Koshima Y; Tsuchiya T; Tamura R; Takahashi M; Ohshima T; Ooka Y
    Cureus; 2024 Aug; 16(8):e66185. PubMed ID: 39108764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction therapy with hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib and pd1 inhibitors in treating hepatocellular carcinoma patients with portal vein tumor thrombosis.
    Fu Y; Peng W; Zhang W; Yang Z; Hu Z; Pang Y; Hu D; Chen J; Wang J; Zhou Z; Xu L; Chen M; Zhang Y
    J Gastroenterol; 2023 Apr; 58(4):413-424. PubMed ID: 36894804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic Arterial Infusion Chemotherapy Combined Lenvatinib and PD-1 Inhibitor Showed Improved Survival for Infiltrative Hepatocellular Carcinoma: A Multicenter Cohort Study.
    Li R; Wang X; Li H; Wang M; Wang J; Wang W; Zhou Q
    J Hepatocell Carcinoma; 2024; 11():1727-1740. PubMed ID: 39281003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multicenter Phase II Trial of Lenvatinib plus Hepatic Intra-Arterial Infusion Chemotherapy with Cisplatin for Advanced Hepatocellular Carcinoma: LEOPARD.
    Ikeda M; Yamashita T; Ogasawara S; Kudo M; Inaba Y; Morimoto M; Tsuchiya K; Shimizu S; Kojima Y; Hiraoka A; Nouso K; Aikata H; Numata K; Sato T; Okusaka T; Furuse J
    Liver Cancer; 2024 Apr; 13(2):193-202. PubMed ID: 38751550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Importance of Regimens in Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macrovascular Invasion.
    Niizeki T; Iwamoto H; Shirono T; Shimose S; Nakano M; Okamura S; Noda Y; Kamachi N; Hiroyuki S; Sakai M; Kuromatsu R; Koga H; Torimura T
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival Benefit of Lenvatinib Plus PD-1 Inhibitor with or Without HAIC in Advanced Hepatocellular Carcinoma Beyond Oligometastasis: a Multicenter Cohort Study.
    Wang M; Zhou Q; Li H; Liu M; Li R; Wang W; Wang X; Huang J; Duan F
    Immunotargets Ther; 2024; 13():447-459. PubMed ID: 39280092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for HCC refractory to TACE.
    Diao L; Wang C; You R; Leng B; Yu Z; Xu Q; Cheng Y; Yin G
    J Gastroenterol Hepatol; 2024 Apr; 39(4):746-753. PubMed ID: 38240156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic arterial infusion chemotherapy plus lenvatinib with or without programmed cell death protein-1 inhibitors for advanced cholangiocarcinoma.
    Wei Z; Wang Y; Wu B; Liu Y; Wang Y; Ren Z; Yang X; Chen Q; Zhang Y
    Front Immunol; 2023; 14():1235724. PubMed ID: 37720223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HAIC Combined with lenvatinib plus PD-1 versus lenvatinib Plus PD-1 in patients with high-risk advanced HCC: a real-world study.
    Chang X; Li X; Sun P; Li Z; Sun P; Ning S
    BMC Cancer; 2024 Apr; 24(1):480. PubMed ID: 38627684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic arterial infusion chemotherapy enhances the efficacy of lenvatinib plus PD-1 inhibitors in hepatocellular carcinoma patients with tumor thrombosis in the inferior vena cava and/or right atrium.
    Lou Y; Zhang X; Sun P; Chang X
    Acad Radiol; 2024 Sep; ():. PubMed ID: 39278760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic arterial infusion chemotherapy using low-dose 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma.
    Ueshima K; Kudo M; Takita M; Nagai T; Tatsumi C; Ueda T; Kitai S; Ishikawa E; Yada N; Inoue T; Hagiwara S; Minami Y; Chung H
    Oncology; 2010 Jul; 78 Suppl 1():148-53. PubMed ID: 20616598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity.
    Iwamoto H; Shimose S; Shirono T; Niizeki T; Kawaguchi T
    Clin Mol Hepatol; 2023 Jul; 29(3):593-604. PubMed ID: 36775834
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.
    Kudo M; Ueshima K; Saeki I; Ishikawa T; Inaba Y; Morimoto N; Aikata H; Tanabe N; Wada Y; Kondo Y; Tsuda M; Nakao K; Ito T; Hosaka T; Kawamura Y; Kuzuya T; Nojiri S; Ogawa C; Koga H; Hino K; Ikeda M; Moriguchi M; Hisai T; Yoshimura K; Furuse J; Arai Y
    Liver Cancer; 2024 Feb; 13(1):99-112. PubMed ID: 38344448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma.
    Park JY; Ahn SH; Yoon YJ; Kim JK; Lee HW; Lee DY; Chon CY; Moon YM; Han KH
    Cancer; 2007 Jul; 110(1):129-37. PubMed ID: 17508408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis on Efficacy of Hepatic Artery Infusion Chemotherapy with or without Lenvatinib for Unresectable Hepatocellular Carcinoma.
    Yuan W; Yue W; Wen H; Wang X; Wang Q
    Eur Surg Res; 2023; 64(2):268-277. PubMed ID: 36812900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatic arterial infusion chemotherapy, lenvatinib plus programmed cell death protein-1 inhibitors: A promising treatment approach for high-burden hepatocellular carcinoma.
    Fu S; Xu Y; Mao Y; He M; Chen Z; Huang S; Li D; Lv Y; Wu J
    Cancer Med; 2024 May; 13(9):e7105. PubMed ID: 38686567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors.
    Guan R; Zhang N; Deng M; Lin Y; Huang G; Fu Y; Zheng Z; Wei W; Zhong C; Zhao H; Mei J; Guo R
    Int J Surg; 2024 Jul; 110(7):4062-4073. PubMed ID: 38549220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenvatinib plus drug-eluting bead transarterial chemoembolization with/without hepatic arterial infusion chemotherapy for hepatocellular carcinoma larger than 7 cm with major portal vein tumor thrombosis: a multicenter retrospective cohort study.
    Cai M; Liang L; Zhang J; Chen N; Huang W; Guo Y; Hong X; Lin L; Liu Y; Dan C; Deng H; Liu X; Zhou J; Chen Y; Chen H; Zhu K
    Int J Surg; 2024 Jun; 110(12):7860-70. PubMed ID: 38869974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors for advanced hepatocellular carcinoma with macrovascular invasion.
    Zhang Y; Zhang H; Xu H; Wang Y; Feng L; Yi F
    World J Surg Oncol; 2024 May; 22(1):122. PubMed ID: 38711095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic arterial infusion chemotherapy using high-dose 5-fluorouracil and cisplatin with or without interferon-alpha for the treatment of advanced hepatocellular carcinoma with portal vein tumor thrombosis.
    Eun JR; Lee HJ; Moon HJ; Kim TN; Kim JW; Chang JC
    Scand J Gastroenterol; 2009; 44(12):1477-86. PubMed ID: 19958061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.